In a report released today, Justin Keywood from Stifel Nicolaus upgraded Knight Therapeutics (KHTRF – Research Report) to Buy, with a price target of C$6.50. The company’s shares closed last Wednesday at $4.10.
According to TipRanks.com, Keywood is ranked #395 out of 7578 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $6.32 average price target.
The company has a one-year high of $4.64 and a one-year low of $3.95. Currently, Knight Therapeutics has an average volume of 14.37K.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KHTRF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.